Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
The firm operates across multiple legal jurisdictions, through the provision of psychedelic therapy and experience, as well as market-leading Functional Mushroom brands and product portfolio.
The vertically-integrated company does a little bit everything. categorized in four different groups:
- Psyence Therapeutics: Medicinal formulations and therapies to treat mental health disorders in a clinical environment.
- Psyence Production: Commercially licensed and scalable non-synthetic GMP psilocybin cultivation and processing facility.
- Psyence Experience: Premium retreats in Jamaica and Southern Africa reconnect people to nature, nourishing mind and body, and elevating consciousness.
- Psyence Function: Health and wellbeing products that support the Psyence purpose and are based on proprietary formulations.
Stock Performance
Psyence Group News 36 articles
- Psyence Group Announces Share Consolidation
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
- Psyence Group Enters Into Agreements With Its NASDAQ-Listed Associate, Psyence Biomedical, To Settle Outstanding Obligations
- Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
- Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
- Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
- Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
- Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
- Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
- Psyence Group Announces Resignation of Board Member
- Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
- Psyence Expands Psilocybin Production Capability
- Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement
- Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
- Psyence Group Corporate Update
- Psyence Appoints Intellectual Property Expert to Its Board of Directors
- Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note
- Psyence Group Announces Cantheon Capital Private Placement
- Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
- Psyence and Eden Labs Announce Extraction and Product Development Collaboration
- Psyence Signs Letter of Intent with Australian CRO iNGENū
- Filament Health and Psyence Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
- Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor
- GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works
- Psyence Group Announces Strategic Private Placement
- Psyence Group Completes Export of Psilocybin Mushrooms to Portugal
- Psyence Group Completes Export of Psilocybin Mushrooms to Canada
- Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency
- Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
- Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
- Psyence Group Launches its Functional Mushroom Brand, “Goodmind”